Thomas Campi | CEO
Modulant Biosciences

Dr. Tom Campi is the CEO of Modulant Biosciences, an animal health biotechnology company focusing on therapies for infectious and chronic diseases. The current pipeline includes drugs for FIP, a fatal coronavirus in cats; Parvo, a serious enteric disease in dogs, PRRSv, a continuing problem for the swine industry; and in oncology, a series of drugs with broad effectiveness.   He is also the Chief Scientific Officer for Veloviapharma, a drug development company focusing on companion animal health therapeutics. Dr. Campi was formerly Head of Research & Regulatory Affairs for Huvepharma. His responsibilities included establishing regulatory strategies and directing R&D for vaccines, pioneer and generic drugs for food animals. Tom also worked for Elanco Animal Health and held various positions over a career spanning more than 25 years. His roles included directing regulatory affairs in the US and Western Europe, and directing Technology Acquisitions, where he was responsible for leading a team of scientists who evaluated novel medicines and vaccine candidates for further development in companion and food animals. Tom received his DVM and Master of Preventive Veterinary Medicine (MPVM) degrees from the University of California, Davis.